MeSH term
Frequency | Condition_Probility | Animals | 22 | 0.0 |
Female | 58 | 0.0 |
Humans | 88 | 0.0 |
Ovary/physiology | 2 | 9.0 |
Pregnancy | 7 | 0.0 |
Protein Isoforms | 2 | 0.0 |
Receptors, Progesterone/*physiology | 4 | 36.0 |
*Reproduction | 2 | 10.0 |
*DNA Methylation | 2 | 0.0 |
Estrogen Receptor beta | 2 | 2.0 |
Male | 15 | 0.0 |
Polymerase Chain Reaction | 3 | 0.0 |
RNA, Messenger/metabolism | 2 | 0.0 |
Receptors, Progesterone/*genetics | 2 | 9.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 4 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 38 | 0.0 |
Tumor Cells, Cultured | 10 | 0.0 |
Image Processing, Computer-Assisted | 4 | 1.0 |
Immunoenzyme Techniques | 7 | 0.0 |
Ki-67 Antigen/metabolism | 2 | 0.0 |
Prognosis | 5 | 0.0 |
Receptors, Estrogen/metabolism | 2 | 0.0 |
Receptors, Progesterone/metabolism | 4 | 2.0 |
Adolescent | 2 | 0.0 |
Adult | 23 | 0.0 |
Aged | 13 | 0.0 |
Aged, 80 and over | 5 | 0.0 |
Analysis of Variance | 2 | 0.0 |
Biological Markers | 2 | 0.0 |
Comparative Study | 19 | 0.0 |
Middle Aged | 15 | 0.0 |
Prospective Studies | 3 | 0.0 |
Binding Sites | 5 | 0.0 |
Research Support, Non-U.S. Gov't | 41 | 0.0 |
Trans-Activators/genetics/*metabolism | 2 | 0.0 |
Dose-Response Relationship, Drug | 2 | 0.0 |
Estradiol/metabolism | 2 | 2.0 |
Hamsters | 2 | 0.0 |
Hormone Antagonists/chemistry/*pharmacology | 2 | 100.0 |
Transcription, Genetic/*drug effects | 3 | 0.0 |
Amino Acid Sequence | 8 | 0.0 |
Molecular Sequence Data | 13 | 0.0 |
Mutation | 4 | 0.0 |
Heat | 2 | 0.0 |
Immunohistochemistry | 12 | 0.0 |
Receptors, Estrogen/*metabolism | 7 | 3.0 |
Receptors, Progesterone/*metabolism | 11 | 9.0 |
Reproducibility of Results | 2 | 0.0 |
Time Factors | 3 | 0.0 |
HIV-1/*enzymology | 3 | 17.0 |
Models, Molecular | 2 | 0.0 |
Protein Conformation | 2 | 0.0 |
Substrate Specificity | 2 | 0.0 |
Macaca mulatta | 2 | 0.0 |
Receptors, Estrogen/analysis | 6 | 1.0 |
Receptors, Progesterone/analysis | 5 | 2.0 |
Tumor Markers, Biological/*analysis | 2 | 0.0 |
Consensus Sequence | 2 | 0.0 |
Phosphorylation | 3 | 0.0 |
Promegestone/pharmacology | 3 | 18.0 |
Proteasome Endopeptidase Complex | 2 | 0.0 |
Endometrium/*metabolism | 2 | 2.0 |
Receptors, Progesterone/*biosynthesis | 2 | 12.0 |
Base Sequence | 9 | 0.0 |
Cattle | 3 | 0.0 |
Cell Line | 7 | 0.0 |
Kinetics | 4 | 0.0 |
Rats | 4 | 0.0 |
Antineoplastic Agents, Hormonal/*therapeutic use | 2 | 2.0 |
Breast Neoplasms/*drug therapy | 2 | 3.0 |
Receptors, Estrogen/*analysis | 9 | 3.0 |
Receptors, Progesterone/*analysis | 12 | 5.0 |
Retrospective Studies | 5 | 0.0 |
Nuclear Proteins/metabolism | 2 | 0.0 |
Promoter Regions (Genetics) | 2 | 0.0 |
Protein Binding | 3 | 0.0 |
Signal Transduction | 2 | 0.0 |
Blotting, Western | 3 | 0.0 |
DNA Primers/chemistry | 3 | 0.0 |
Estradiol/*pharmacology | 2 | 0.0 |
Receptors, Progesterone/*immunology | 2 | 100.0 |
Blotting, Southern | 2 | 0.0 |
Sequence Homology, Amino Acid | 2 | 0.0 |
Cell Division | 2 | 0.0 |
Menstrual Cycle | 2 | 1.0 |
Cytosol/metabolism | 3 | 0.0 |
Gene Expression | 2 | 0.0 |
Mice | 7 | 0.0 |
*Trans-Activation (Genetics) | 2 | 0.0 |
Transcription, Genetic | 2 | 0.0 |
Mammary Tumor Virus, Mouse/genetics | 2 | 5.0 |
*Mutation | 2 | 0.0 |
Transfection | 5 | 0.0 |
Fibroblasts/enzymology | 2 | 1.0 |
Genes, Structural | 3 | 0.0 |
Ribose-Phosphate Pyrophosphokinase/*genetics/metabolism | 2 | 66.0 |
Linkage (Genetics) | 2 | 0.0 |
Point Mutation | 3 | 0.0 |
Ribose-Phosphate Pyrophosphokinase/*genetics | 3 | 33.0 |
*X Chromosome | 3 | 0.0 |
Remission Induction | 2 | 0.0 |
Treatment Outcome | 3 | 0.0 |
Chromosome Mapping | 3 | 0.0 |
*Point Mutation | 2 | 0.0 |
Mifepristone/pharmacology | 2 | 2.0 |
Endopeptidases/*metabolism | 2 | 1.0 |
Species Specificity | 2 | 0.0 |
Breast Neoplasms | 2 | 0.0 |
Promegestone/metabolism | 2 | 16.0 |
Estradiol/blood | 2 | 0.0 |
Radioligand Assay | 2 | 0.0 |
DNA/genetics | 2 | 0.0 |
X Chromosome | 2 | 0.0 |
Immunohistochemistry/methods | 2 | 0.0 |
Staining and Labeling | 2 | 0.0 |
Tumor Markers, Biological/metabolism | 2 | 0.0 |
Antibodies, Monoclonal/diagnostic use | 2 | 0.0 |
Breast Neoplasms/*metabolism | 2 | 0.0 |
Evaluation Studies | 2 | 0.0 |
Antineoplastic Combined Chemotherapy Protocols/therapeutic use | 2 | 0.0 |
Cells, Cultured | 3 | 0.0 |
Cell Nucleus/metabolism | 2 | 0.0 |
